ePrints

Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease

Lookup NU author(s): Professor Camille CarrollORCiD, Professor Nicola PaveseORCiD

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Abstract

© 2022 The Authors. Aim: This subanalysis of the OPTIPARK study aimed to confirm the effectiveness and safety of opicapone in patients with Parkinson's disease and motor fluctuations in clinical practice specifically in the UK and to assess the impact of opicapone on treatment costs. Methods: Patients received opicapone added to levodopa for 6 months. Clinical outcomes were assessed at 3 and 6 months and treatment costs at 6 months. Results: Most patients' general condition improved at 3 months, with sustained improvements reported at 6 months. Opicapone improved motor and non-motor symptoms at both timepoints, was generally well tolerated and reduced total treatment costs by GBP 3719. Conclusion: Opicapone added to levodopa resulted in clinical improvements and reduced treatment costs across UK clinical practice.

Publication metadata

Author(s): Schofield C, Chaudhuri KR, Carroll C, Sharma JC, Pavese N, Evans J, Foltynie T, Reichmann H, Zurowska L, Soares-Da-Silva P, Lees A

Publication type: Article

Publication status: Published

Journal: Neurodegenerative Disease Management

Year: 2022

Volume: 12

Issue: 2

Pages: 77-91

Print publication date: 01/04/2022

Online publication date: 21/03/2022

Acceptance date: 17/02/2022

Date deposited: 03/07/2023

ISSN (print): 1758-2024

ISSN (electronic): 1758-2032

Publisher: Future Medicine Ltd

URL: https://doi.org/10.2217/nmt-2021-0057

DOI: 10.2217/nmt-2021-0057

PubMed id: 35313124

Altmetrics

Funding

Share